Literature DB >> 20947691

Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation.

Hisayuki Yokoyama, Andreas Lundqvist, Su Su, Richard Childs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20947691      PMCID： PMC2974593          DOI： 10.1182/blood-2010-06-291104

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  1 in total

1.  Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.

Authors:  Stephan Metzelder; Ying Wang; Ellen Wollmer; Michael Wanzel; Sabine Teichler; Anuhar Chaturvedi; Martin Eilers; Erich Enghofer; Andreas Neubauer; Andreas Burchert
Journal:  Blood       Date:  2009-04-23       Impact factor: 22.113
  1 in total
  8 in total

1.  Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.

Authors:  Manish Sharma; Farhad Ravandi; Ulas Darda Bayraktar; Alexandre Chiattone; Qaiser Bashir; Sergio Giralt; Julianne Chen; Muzaffar Qazilbash; Partow Kebriaei; Marina Konopleva; Michael Andreeff; Jorge Cortes; Deborah McCue; Hagop Kantarjian; Richard E Champlin; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-20       Impact factor: 5.742

2.  Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.

Authors:  Yi-Bin Chen; Shuli Li; Andrew A Lane; Christine Connolly; Candice Del Rio; Betsy Valles; Morgan Curtis; Karen Ballen; Corey Cutler; Bimalangshu R Dey; Areej El-Jawahri; Amir T Fathi; Vincent T Ho; Amy Joyce; Steven McAfee; Michelle Rudek; Trivikram Rajkhowa; Sigitas Verselis; Joseph H Antin; Thomas R Spitzer; Mark Levis; Robert Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-17       Impact factor: 5.742

3.  OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.

Authors:  Xiangxuan Zhao; Changhai Tian; William M Puszyk; Olorunseun O Ogunwobi; Mengde Cao; Ton Wang; Roniel Cabrera; David R Nelson; Chen Liu
Journal:  Lab Invest       Date:  2012-10-29       Impact factor: 5.662

4.  The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.

Authors:  Andrzej Lange; Emilia Jaskula; Janusz Lange; Grzegorz Dworacki; Dorota Nowak; Aleksandra Simiczyjew; Monika Mordak-Domagala; Mariola Sedzimirska
Journal:  PLoS One       Date:  2018-01-05       Impact factor: 3.240

5.  Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases.

Authors:  Paulo Vidal Campregher; Vinicius Renan Pinto de Mattos; Marco Aurélio Salvino; Fabio Pires de Souza Santos; Nelson Hamerschlak
Journal:  Einstein (Sao Paulo)       Date:  2017-07-24

Review 6.  Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia.

Authors:  Andreas Burchert
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

Review 7.  FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation.

Authors:  Amanda Blackmon; Ibrahim Aldoss; Brian J Ball
Journal:  Blood Lymphat Cancer       Date:  2022-09-06

Review 8.  Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Ali Bazarbachi; Gesine Bug; Frederic Baron; Eolia Brissot; Fabio Ciceri; Iman Abou Dalle; Hartmut Döhner; Jordi Esteve; Yngvar Floisand; Sebastian Giebel; Maria Gilleece; Norbert-Claude Gorin; Elias Jabbour; Mahmoud Aljurf; Hagop Kantarjian; Mohamed Kharfan-Dabaja; Myriam Labopin; Francesco Lanza; Florent Malard; Zinaida Peric; Thomas Prebet; Farhad Ravandi; Annalisa Ruggeri; Jaime Sanz; Christoph Schmid; Roni Shouval; Alexandros Spyridonidis; Jurjen Versluis; Norbert Vey; Bipin N Savani; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2020-04-02       Impact factor: 9.941
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.